ACHIEVING VIROLOGICAL CONTROL IN PAN-RESISTANT HIV-1 INFECTION: A CASE SERIES
We report findings from heavily treatment-experienced PLWH with a pan-resistant HIV-1 infection, who achieved virological control once introduced injections of ibalizumab, that is free from cross-resistance with all the antiretroviral drugs available and ensures patient adherence due to a close monitoring attributable to the route of administration, combined with recycled enfuvirtide and an optimized background regimen, selected on the basis of an accurate evaluation of resistance mutations. Please refer to DOI: https://doi.org/10.1016/j.ebiom.2022.103906
Steps to reproduce
We selected the three PLWH with a documented poor virological response to previous antiretroviral therapies, who started ibalizumab, an anti-CD4 monoclonal antibody, combined with an optimized background therapy.